Company analyses

Impala Nordic publishes equity analysis on OncoZenge AB (publ)

2025-08-12

Impala Nordic has published an updated equity research report on OncoZenge, where we present our view on the Company’s recent developments.

OncoZenge is a Swedish research company developing BupiZenge™, a pain-relieving lozenge intended for the treatment of oral mucositis. The Company plans to conduct a European Phase 3 trial, which will form the basis for marketing authorisation of BupiZenge™ in Europe.

Impala Nordic publishes equity analysis on Brain+ A/S

2025-06-25

Impala Nordic initiates coverage on Brain+, a Danish life-science company pioneering digital solutions for improved dementia care, helping people affected by dementia live better lives. The Company is developing Ayla, the world's first dementia-care platform, aiming to reach operational break-even by mid 2026.

Impala Nordic publishes analysis on ChargePanel AB (publ)

2025-06-24

Impala Nordic releases an updated analysis of ChargePanel AB as a result of the Company's recent successes, including the agreements with Eways and Arval, which are expected to contribute annual revenues in the millions.

Impala Nordic publishes analysis on Lappland Guldprospektering AB (publ)

2025-06-04

Impala Nordic has prepared a company analysis on Lappland Guldprospektering AB (publ). Lappland Guldprospektering is a Swedish company active in gold prospecting with a focus on developing and conducting gold mining on a larger scale in Sweden and the rest of the Nordic region.

Impala Nordic initiates analysis coverage of DUG Foodtech AB (publ)

2025-05-13

Impala Nordic initiates analysis coverage of DUG Foodtech, a company that develops and sells alternative dairy products based on potatoes. The main focus is on beverages, where the company's DUG brand offers an alternative to milk and other non-dairy-based beverages.

Impala Nordic has prepared a summary of the investment case in Diamyd Medical AB (publ)

2025-04-17

Diamyd Medical is a biotechnology company that develops precision medicine therapies for the prevention and treatment of autoimmune type 1 diabetes. The Company is currently conducting a rights issue of SEK 208 million to secure capital ahead of the early reading of the Company's phase 3 study DIAGNODE-3 in March 2026.

Impala Nordic initiates analysis coverage at Prebona AB (publ)

2025-03-20

Impala Nordic initiates analysis coverage at Prebona AB (publ). Prebona is a company that develops environmentally friendly and functional products, including for eliminating bad odors and surface coatings. Impala Nordic sees several exciting value drivers ahead, including expected cash flow positivity after the end of Q1.

Impala Nordic publishes analysis on Carbiotix AB (publ)

2024-12-02

Carbiotix is active in the extraction of prebiotics from plant-based side streams, proteins and other active ingredients. The company is currently focusing on commercializing and out-licensing the up-cycling service NutraCycle.

Impala Nordic initiates analytical coverage of ZignSec AB (publ)

2024-07-10

Impala Nordic initiates analytical coverage of ZignSec AB (publ). ZignSec is a leading player in digital solutions for AML and KYC compliance. The group, which consists of several companies, jointly offers a wide range of RegTech solutions. The company is listed on First North Stockholm.

Impala Nordic publishes analysis on Hoi Publishing AB (publ)

2024-04-08

Impala Nordic initiates analysis coverage on Hoi Publishing AB (publ). Hoi is a fast-growing Nordic publishing group with a unique hybrid business model and a successful acquisition strategy that drives significant revenue growth and improved profitability. The company is listed on NGM.

Impala Nordic publishes analysis on Adverty AB (publ)

2024-03-06

Adverty is a pioneer in In-Play advertising and has developed the world's first programmatic platform for automated advertising in mobile games. The company has experienced impressive growth from 5 million SEK in 2021 to over 50 million SEK in 2023, with a positive operating profit reported for the fourth quarter of 2023. Adverty shows no signs of slowing down, indicating a promising future for 2024.

Impala Nordic initiates analysis coverage of OncoZenge AB (publ)

2024-01-16

Impala Nordic initiates analysis coverage of OncoZenge AB (publ). OncoZenge is in an intensive phase of preparing BupiZenge for phase 3 studies and securing a study partner who can also promote a possible market launch in Europe. OncoZenge is currently working to secure PRIME status with the EMA, which can facilitate the regulatory process. With a drug candidate that has the potential to improve the quality of life for people with oral mucositis, OncoZenge faces exciting future opportunities.

Impala Nordic initiates analysis coverage of ChargePanel AB (publ)

2023-12-21

Impala Nordic initiates analysis coverage of ChargePanel AB (publ). ChargePanel is focused on increasing the number of recurring revenues and connected charging points and is expected to increase its revenues and market share, especially with increased demand for charging infrastructure for electric vehicles. Management's goal is to achieve profitability and positive cash flow by the end of 2024, which is a trigger for the case.

Impala Nordic initiates analysis coverage at Diagonal Bio AB (publ)

2023-07-24

Impala Nordic starts analytical coverage at Diagonal Bio AB (publ). The company has a strong pipeline ahead and aims to obtain CE marking for LAMPlify and then launch and commercialize its LAMPlify system for biomarker identification in 2023.

Impala Nordic initiates analysis coverage of Blick Global Group

2023-04-11

Impala Nordic initiates analysis coverage of Blick Global Group AB (publ). Blick Global Group aims to expand by acquiring 1-3 companies per year. The company has shown impressive annual revenue growth of 25% over the past three years and, supported by structural trends such as deregulation and digitalization, the company is facing an exciting growth journey.